Podcast Episodes
Back to SearchWhat’s the latest on the national outbreak of Measles in the US?
Episode 527
The measles outbreak stands at 1,227 confirmed cases in 2025 so far—nearly five times the total for all of 2024—mostly among unvaccinated individuals…
1 year, 3 months ago
ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More
Episode 526
Drs. Yuan and Callahan discuss data presented at ASCO 2025 about DESTINY-Breast06, SHR-A1811, and TQB2101, along with real-world data on rechallengin…
1 year, 3 months ago
ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast09, PATINA, MINI Trial, and More
Episode 525
Drs. Callahan and Yuan discuss data presented at ASCO 2025 on DESTINY-Breast09, PATINA, and MINI Trial, the utility of PFS-2 as an endpoint, and sequ…
1 year, 3 months ago
Highlights From ATS 2025: New and Emerging Therapies, Biomarkers, and Imaging for ILDs
Episode 524
Drs. Zaman and Podolanczuk discuss data for new and emerging therapies for ILD presented at ATS 2025, including nerandomilast, inhaled therapies for …
1 year, 3 months ago
Highlights From ATS 2025: Approach to the Evaluation and Management of Interstitial Lung Abnormalities—The Official ATS Clinical Statement
Episode 523
Tanzira Zaman, MD and Elizabeth Volkmann, MD, MS discuss the new official American Thoracic Society Clinical Statement on the diagnosis and managemen…
1 year, 3 months ago
Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic?
Episode 522
The FDA approved lenacapavir, a twice-yearly injectable PrEP shown to be 99% effective in preventing HIV, though high cost may limit global access. A…
1 year, 3 months ago
Emerging and Future Biomarkers for Interstitial Lung Disease
Episode 521
Drs. Sood and Liu discuss emerging and investigational biomarkers for interstitial lung disease and their potential utility as predictors of progress…
1 year, 3 months ago
Advances and Future Treatment Targets for Interstitial Lung Disease
Episode 520
Gabrielle Liu, MD, MS and Namita Sood, MD, FCCP discuss advances and future treatment targets for interstitial lung disease including some that are s…
1 year, 3 months ago
Can an oral diabetes drug reduce hepatic scarring from MASH?
Episode 519
A Chinese trial found dapagliflozin improved MASH outcomes, with higher resolution and fibrosis improvement rates than placebo. A JAMA Network Open s…
1 year, 4 months ago
The Role of MRD Testing in CLL
Episode 518
Drs. Brander and Cohen discuss the growing role of measurable residual disease (MRD) testing in CLL and its clinical implications.
1 year, 4 months ago